DE60017894D1 - Diaminothiazole und ihre verwendung zur inhibierung von proteinkinasen - Google Patents

Diaminothiazole und ihre verwendung zur inhibierung von proteinkinasen

Info

Publication number: DE60017894D1
Authority: DE; Germany
Prior art keywords: diaminothiazole; inhibition; protein kinases; kinases; protein
Prior art date: 1999-06-04
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Fee Related

Application number

DE60017894T

Other languages

English (en)

Other versions

DE60017894T2 (de

Inventor

Song Chu

Andrew Alegria

Lee Bender

Pritchett Benedict

J Borchardt

Steven Kania

David Nambu

Anna Maria Tempczyk-Russell

Sepehr Sarshar

Dilip Bhumralkar

Peng Zhengwei

Michelle Yang

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Agouron Pharmaceuticals LLC

Original Assignee

Agouron Pharmaceuticals LLC

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-06-04

Filing date

2000-06-02

Publication date

2005-03-10

2000-06-02 Application filed by Agouron Pharmaceuticals LLC filed Critical Agouron Pharmaceuticals LLC

2005-03-10 Application granted granted Critical

2005-03-10 Publication of DE60017894D1 publication Critical patent/DE60017894D1/de

2005-12-29 Publication of DE60017894T2 publication Critical patent/DE60017894T2/de

2020-06-03 Anticipated expiration legal-status Critical

Status Expired - Fee Related legal-status Critical Current

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6536—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and sulfur atoms with or without oxygen atoms, as the only ring hetero atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6536—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and sulfur atoms with or without oxygen atoms, as the only ring hetero atoms
- C07F9/6539—Five-membered rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Thiazole And Isothizaole Compounds (AREA)

DE60017894T 1999-06-04 2000-06-02 Diaminothiazole und ihre verwendung zur inhibierung von proteinkinasen Expired - Fee Related DE60017894T2 (de)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US13781099P	1999-06-04	1999-06-04
US137810P		1999-06-04
PCT/US2000/015188 WO2000075120A1 (en)	1999-06-04	2000-06-02	Diaminothiazoles and their use for inhibiting protein kinases

Publications (2)

Publication Number	Publication Date
DE60017894D1 true DE60017894D1 (de)	2005-03-10
DE60017894T2 DE60017894T2 (de)	2005-12-29

Family

ID=22479135

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DE60017894T Expired - Fee Related DE60017894T2 (de)	1999-06-04	2000-06-02	Diaminothiazole und ihre verwendung zur inhibierung von proteinkinasen

Country Status (34)

Country	Link
US (1)	US6620828B2 (de)
EP (1)	EP1181283B1 (de)
JP (1)	JP2003501420A (de)
KR (1)	KR20020015333A (de)
CN (1)	CN1359380A (de)
AP (1)	AP2001002341A0 (de)
AT (1)	ATE288424T1 (de)
AU (1)	AU778071B2 (de)
BG (1)	BG106276A (de)
BR (1)	BR0011585A (de)
CA (1)	CA2371158A1 (de)
CZ (1)	CZ20014213A3 (de)
DE (1)	DE60017894T2 (de)
EA (1)	EA200101268A1 (de)
EE (1)	EE200100659A (de)
ES (1)	ES2234628T3 (de)
HR (1)	HRP20020008A2 (de)
HU (1)	HUP0202897A3 (de)
IL (1)	IL146094A0 (de)
IS (1)	IS6183A (de)
MA (1)	MA25530A1 (de)
MX (1)	MXPA01012483A (de)
NO (1)	NO20015045L (de)
NZ (1)	NZ514881A (de)
OA (1)	OA11959A (de)
PE (1)	PE20010211A1 (de)
PL (1)	PL352714A1 (de)
SK (1)	SK17302001A3 (de)
SV (1)	SV2002000096A (de)
UA (1)	UA71971C2 (de)
UY (1)	UY26190A1 (de)
WO (1)	WO2000075120A1 (de)
YU (1)	YU85601A (de)
ZA (1)	ZA200108291B (de)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20020150921A1 (en) *	1996-02-09	2002-10-17	Francis Barany	Detection of nucleic acid sequence differences using the ligase detection reaction with addressable arrays
DE69835241T2 (de) *	1997-10-27	2007-05-31	Agouron Pharmaceuticals, Inc., La Jolla	4-Aminothiazol Derivate, deren Herstellung und deren Verwendung als Inhibitoren Cyclin-abhängiger Kinasen
US6262096B1 (en)	1997-11-12	2001-07-17	Bristol-Myers Squibb Company	Aminothiazole inhibitors of cyclin dependent kinases
US20040226056A1 (en) *	1998-12-22	2004-11-11	Myriad Genetics, Incorporated	Compositions and methods for treating neurological disorders and diseases
HUP0202708A3 (en)	1999-04-15	2004-12-28	Bristol Myers Squibb Co	Cyclic protein tyrosine kinase inhibitors, pharmaceutical compositions containing them and their use
US7125875B2 (en)	1999-04-15	2006-10-24	Bristol-Myers Squibb Company	Cyclic protein tyrosine kinase inhibitors
HUP0303538A2 (hu)	2000-12-21	2005-02-28	Bristol-Myers Squibb Co.	Tirozin kinázok Tec családjának tiazolil-vegyület inhibitorai és ezeket tartalmazó gyógyszerkészítmények
US6756374B2 (en)	2001-01-22	2004-06-29	Hoffmann-La Roche Inc.	Diaminothiazoles having antiproliferative activity
UA76977C2 (en)	2001-03-02	2006-10-16	Icos Corp	Aryl- and heteroaryl substituted chk1 inhibitors and their use as radiosensitizers and chemosensitizers
AU2002313633B2 (en) *	2001-06-08	2007-03-01	Cytovia, Inc.	Substituted 3-aryl-5-aryl-[1,2,4]-oxadiazoles and analogs
CA2474322A1 (en) *	2002-01-25	2003-07-31	Kylix Pharmaceuticals B.V.	4(hetero-) aryl substituted (thia-/oxa-/pyra) zoles for inhibition of tie-2
US6818663B2 (en) *	2002-05-17	2004-11-16	Hoffmann-La Roches	Diaminothiazoles
WO2004014903A1 (en)	2002-08-02	2004-02-19	Ab Science	2-(3-aminoaryl)amino-4-aryl-thiazoles and their use as c-kit inhibitors
US8450302B2 (en)	2002-08-02	2013-05-28	Ab Science	2-(3-aminoaryl) amino-4-aryl-thiazoles and their use as c-kit inhibitors
AR041867A1 (es)	2002-11-01	2005-06-01	Takeda Pharmaceutical	Agente para prevenir o tratar neuropatia
CA2516234A1 (en) *	2003-02-21	2004-09-02	Pfizer Inc.	N-heterocyclyl-substituted amino-thiazole derivatives as protein kinase inhibitors
US7078419B2 (en)	2003-03-10	2006-07-18	Boehringer Ingelheim Pharmaceuticals, Inc.	Cytokine inhibitors
ES2887054T3 (es)	2003-04-11	2021-12-21	Ptc Therapeutics Inc	Compuesto de ácido 1,2,4-oxadiazol benzoico y su uso para la supresión sin sentido y el tratamiento de enfermedades
WO2004092217A1 (en) *	2003-04-17	2004-10-28	Pfizer Inc.	Crystal structure of vegfrkd: ligand complexes and methods of use thereof
EP1644323B1 (de) *	2003-07-07	2015-03-18	Georgetown University	Histondeacetylaseinhibitoren und verfahren zu deren anwendung
JP5010917B2 (ja) *	2003-08-29	2012-08-29	エグゼリクシス，インコーポレイテッド	ｃ−Ｋｉｔ調節因子および使用方法
PT1680140E (pt) *	2003-10-16	2011-05-31	Imclone Llc	Inibidores do receptor-1 do factor de crescimento de fibroblastos e m?todos de tratamento destes
AU2005205201B2 (en) *	2004-01-12	2011-05-12	Merck Serono Sa	Thiazole derivatives and use thereof
WO2005108370A1 (ja) *	2004-04-16	2005-11-17	Ajinomoto Co., Inc.	ベンゼン化合物
US7211576B2 (en)	2004-04-20	2007-05-01	Hoffmann-La Roche Inc.	Diaminothiazoles
US7737184B2 (en) *	2004-07-12	2010-06-15	Merck Sharp & Dohme Corp.	Histone deacetylase inhibitors
BRPI0610341A2 (pt)	2005-05-24	2010-06-15	Serono Lab	derivados de tiazol e uso dos mesmos
KR20080015114A (ko)	2005-05-24	2008-02-18	라보라뚜와르 세로노 에스. 에이.	티아졸 유도체 및 그것의 용도
DK2774925T3 (en)	2005-11-08	2017-02-27	Vertex Pharma	Heterocyclic modulators of ATP binding cassette transporters
ES2398319T3 (es) *	2005-12-28	2013-03-15	Vertex Pharmaceuticals Incorporated	Derivados de 1-(benzo[D][1,3]dioxol-5-il)-N-(fenil)ciclopropano-carboxamida y compuestos relacionados como moduladores de transportadores de casetes de unión a ATP para el tratamiento de la fibrosis quística
AU2012244242B2 (en) *	2005-12-28	2015-05-21	Vertex Pharmaceuticals Incorporated	1-(benzo [D] [1,3] dioxol-5-yl) -N- (phenyl) cyclopropane- carboxamide derivatives and related compounds as modulators of ATP-Binding Cassette transporters for the treatment of Cystic Fibrosis
EA200801716A1 (ru) *	2006-01-18	2009-04-28	Амген Инк.	Тиазольные соединения и их применение
WO2007095602A2 (en) *	2006-02-15	2007-08-23	Abbott Laboratories	Novel acetyl-coa carboxylase (acc) inhibitors and their use in diabetes, obesity and metabolic syndrome
JP2009526868A (ja) *	2006-02-15	2009-07-23	アボット・ラボラトリーズ	新規なアセチル−ＣｏＡカルボキシラーゼ（ＡＣＣ）阻害薬およびこれらの糖尿病、肥満および代謝症候群における使用
IN2014CN04406A (de)	2006-03-30	2015-09-04	Ptc Therapeutics Inc
MX2008015457A (es) *	2006-07-07	2009-01-16	Boehringer Ingelheim Int	Derivados de heteroaril substituido en fenil y el uso de los mismos como agentes anti-tumorales.
WO2008080134A2 (en)	2006-12-22	2008-07-03	Rigel Pharmaceuticals, Inc.	4-amin0-2- (hetero) arylamino-5- (hetero) arylthiazoles useful as axl inhibitors
AU2008251504B2 (en)	2007-05-09	2013-07-18	Vertex Pharmaceuticals Incorporated	Modulators of CFTR
EP2176249A2 (de) *	2007-07-02	2010-04-21	Boehringer Ingelheim International GmbH	Neue chemische verbindungen
CL2008001943A1 (es)	2007-07-02	2009-09-11	Boehringer Ingelheim Int	Compuestos derivados de fenil-triazol, inhibidores de enzimas de señales especificas que participan del control de la proliferacion celular; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar cancer, infecciones, enfermedades inflamatorias y autoinmunes.
WO2009011880A2 (en)	2007-07-17	2009-01-22	Amgen Inc.	Heterocyclic modulators of pkb
US7919504B2 (en) *	2007-07-17	2011-04-05	Amgen Inc.	Thiadiazole modulators of PKB
LT2225230T (lt)	2007-12-07	2017-01-25	Vertex Pharmaceuticals Incorporated	3-(6-(1-(2,2-difluorbenzo[d][1,3]dioksol-5-il) ciklopropankarboksamido)-3-metilpiridin-2-il) benzoinės rūgšties kietos formos
EP2639222B1 (de)	2007-12-07	2016-08-31	Vertex Pharmaceuticals Incorporated	Verfahren zur Herstellung von Cycloalkylcarboxamidopyridinbenzoesäuren
JP2011506454A (ja) *	2007-12-13	2011-03-03	グラクソスミスクラインエルエルシー	チアゾールおよびオキサゾールキナーゼ阻害薬
CN102245573B (zh)	2008-02-28	2013-11-20	沃泰克斯药物股份有限公司	作为cftr调节剂的杂芳基衍生物
UA103319C2 (en)	2008-05-06	2013-10-10	Глаксосмитклайн Ллк	Thiazole- and oxazole-benzene sulfonamide compounds
UY32146A (es)	2008-09-29	2010-04-30	Boehringer Ingelheim Int	Derivados de las 5-[4-(1,5-dimetil-1h-pirazol-4-il)-1,2,3-triazol-1-il]-6-metil-nicotinamidas n-(sustituidas) y de las n-{5-[4-(1,5-dimetil-1h-pirazol-4-il)-1,2,3-triazol-1-il]-6-metil-piridin-3-il}-benzamidas sustituidas y composiciones conteniéndolos
AU2010204578B2 (en)	2009-01-16	2016-05-12	Rigel Pharmaceuticals, Inc.	AXL inhibitors for use in combination therapy for preventing, treating or managing metastatic cancer
WO2011048936A1 (ja) *	2009-10-19	2011-04-28	大正製薬株式会社	アミノチアゾール誘導体
EP2552907B1 (de)	2010-03-26	2014-10-22	Boehringer Ingelheim International GmbH	Pyridyltriazole
US9290507B2 (en)	2010-03-26	2016-03-22	Boehringer Ingelheim International Gmbh	B-RAF kinase inhibitors
LT3150198T (lt)	2010-04-07	2021-12-10	Vertex Pharmaceuticals Incorporated	3-(6-(1-(2,2-difluorbenzo[d][1,3]dioksol-5-il) ciklopropankarboksamido)-3-metilpiridin-2-il)benzoinės rūgšties farmacinė kompozicija ir jos įvedimas
US8710055B2 (en)	2010-12-21	2014-04-29	Boehringer Ingelheim International Gmbh	Triazolylphenyl sulfonamides as serine/threonine kinase inhibitors
JP2015504920A (ja)	2012-01-25	2015-02-16	バーテックスファーマシューティカルズインコーポレイテッドＶｅｒｔｅｘＰｈａｒｍａｃｅｕｔｉｃａｌｓＩｎｃｏｒｐｏｒａｔｅｄ	３−（６−（１−（２，２−ジフルオロベンゾ［ｄ］［１，３］ジオキソール−５−イル）シクロプロパンカルボキサミド）−３−メチルピリジン−２−イル）安息香酸の製剤
US9242977B2 (en)	2012-04-26	2016-01-26	Ono Pharmaceutical Co., Ltd.	Trk-inhibiting compound
BR122017003181A2 (pt)	2013-02-19	2019-09-10	Ono Pharmaceutical Co	composto inibidor de trk, composição farmacêutica e medicamento compreendendo dito composto e seu uso para profilaxia e/ou terapia de doença relacionada à trk e/ou para inibir trk
GB201309333D0 (en)	2013-05-23	2013-07-10	Agency Science Tech & Res	Purine diones as WNT pathway modulators
KR102280372B1 (ko)	2013-11-12	2021-07-22	버텍스 파마슈티칼스 인코포레이티드	Cftr 매개된 질환 치료용 약제학적 조성물의 제조 방법
WO2015134711A1 (en)	2014-03-06	2015-09-11	Ptc Therapeutics, Inc.	Pharmaceutical compositions and salts of a 1,2,4-oxadiazole benzoic acid
PL3221692T3 (pl)	2014-11-18	2021-12-06	Vertex Pharmaceuticals Inc.	Sposób przeprowadzania testowania o wysokiej przepustowości za pomocą wysokosprawnej chromatografii cieczowej
CN108348527A (zh)	2015-10-30	2018-07-31	Ptc医疗公司	用于治疗癫痫的方法
WO2018052967A1 (en) *	2016-09-13	2018-03-22	Arbutus Biopharma, Inc.	Substituted chromane-8-carboxamide compounds and analogues thereof, and methods using same
CN111233786B (zh) *	2020-02-04	2021-11-26	中国人民解放军军事科学院军事医学研究院	含五元杂环的苯磺酰胺类化合物及其制备方法和用途
CN121443601A (zh) *	2023-07-03	2026-01-30	英矽智能科技知识产权有限公司	作为cdk2/4/6抑制剂的取代的噻唑化合物及其使用方法
CN116874442B (zh) *	2023-07-27	2025-10-24	武汉呈瑞生物医药科技有限公司	一种有机化合物及其应用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE273062C (de)	1912-04-19	1914-04-20	Deylen Sohn Firma	Vorrichtung zum Schränken von Plattenzündspänen
AU558132B2 (en)	1981-05-27	1987-01-22	Labatt Brewing Co. Ltd.	Malt sterilisation with hydrogen peroxide
WO1986005779A1 (en)	1985-04-03	1986-10-09	Yamanouchi Pharmaceutical Co., Ltd.	Phenylene derivatives
EP0584222B1 (de) *	1991-05-10	1997-10-08	Rhone-Poulenc Rorer International (Holdings) Inc.	Bis mono- und bicyclische aryl- und heteroarylderivate mit inhibierender wirkung auf die egf und/oder pdgf-rezeptor tyrosinkinase
US5681833A (en)	1992-03-24	1997-10-28	Merck, Sharp & Dohme Ltd.	Benzodiazepine derivatives
US5631156A (en)	1994-06-21	1997-05-20	The University Of Michigan	DNA encoding and 18 KD CDK6 inhibiting protein
DE69532817T2 (de)	1994-11-10	2005-01-13	Millenium Pharmaceuticals, Inc., Cambridge	Verwendung von pyrazole verbindungen zur behandlung von glomerulonephritis, krebs, atherosklerose oder restenose
NZ301265A (en)	1995-02-02	1998-12-23	Smithkline Beecham Plc	Indole derivatives as 5ht receptor antagonists, preparation and pharmaceutical compositions thereof
US5710173A (en)	1995-06-07	1998-01-20	Sugen, Inc.	Thienyl compounds for inhibition of cell proliferative disorders
WO1997003967A1 (en)	1995-07-22	1997-02-06	Rhone-Poulenc Rorer Limited	Substituted aromatic compounds and their pharmaceutical use
US5705499A (en)	1995-10-06	1998-01-06	Boehringer Ingelheim Pharmaceuticals, Inc.	8-arylalkyl- and 8-arylheteroalkyl-5,11-dihydro-6H-dipyrido 3,2-B:2',3'-e! 1!diazepines and their use in the treatment of HIV-1 infection
US5733920A (en)	1995-10-31	1998-03-31	Mitotix, Inc.	Inhibitors of cyclin dependent kinases
US5760028A (en)	1995-12-22	1998-06-02	The Dupont Merck Pharmaceutical Company	Integrin receptor antagonists
DE69734149T2 (de)	1996-03-15	2006-07-06	Astrazeneca Ab	Cinoline derivate und verwendung als heilmittel
DE69709493T2 (de)	1996-06-27	2002-10-31	Pfizer Inc., New York	Substituierte Indazolderivate
KR100338610B1 (ko)	1996-09-04	2002-05-27	디. 제이. 우드, 스피겔 알렌 제이	인다졸 유도체 및 포스포디에스터라제 (pde) 유형 iv 및 종양괴사인자 (tnf) 생산의 억제제로서 그의 용도
ID18494A (id)	1996-10-02	1998-04-16	Novartis Ag	Turunan pirazola leburan dan proses pembuatannya
DE69835241T2 (de) *	1997-10-27	2007-05-31	Agouron Pharmaceuticals, Inc., La Jolla	4-Aminothiazol Derivate, deren Herstellung und deren Verwendung als Inhibitoren Cyclin-abhängiger Kinasen
BR9813926A (pt)	1997-11-04	2000-09-19	Pfizer Prod Inc	Substituição de bioisóstero de catecol por indazol em compostos terapeuticamente ativos
CN1281441A (zh)	1997-11-04	2001-01-24	辉瑞产品公司	以在pde4抑制剂中的儿茶酚的吲唑生物等排物置换为基础的治疗活性化合物
US6040321A (en) *	1997-11-12	2000-03-21	Bristol-Myers Squibb Company	Aminothiazole inhibitors of cyclin dependent kinases
DE69923681T2 (de) *	1998-06-18	2006-01-12	Bristol-Myers Squibb Co.	Kohlenstoff substituierte aminothiazole als inhibitoren von cyclin-abhängigen kinasen
ES2211175T3 (es)	1998-09-29	2004-07-01	Wyeth Holdings Corporation	Inhibidores de proteinas de tipo tirosina quinasas a base de 3-cianoquinolinas sustituidas.

2000
- 2000-02-06 UA UA2001129215A patent/UA71971C2/uk unknown
- 2000-06-02 AT AT00942660T patent/ATE288424T1/de not_active IP Right Cessation
- 2000-06-02 JP JP2001501601A patent/JP2003501420A/ja not_active Abandoned
- 2000-06-02 EA EA200101268A patent/EA200101268A1/ru unknown
- 2000-06-02 BR BR0011585-1A patent/BR0011585A/pt not_active IP Right Cessation
- 2000-06-02 WO PCT/US2000/015188 patent/WO2000075120A1/en not_active Ceased
- 2000-06-02 CN CN00808440A patent/CN1359380A/zh active Pending
- 2000-06-02 AP APAP/P/2001/002341A patent/AP2001002341A0/en unknown
- 2000-06-02 PE PE2000000553A patent/PE20010211A1/es not_active Application Discontinuation
- 2000-06-02 OA OA1200100321A patent/OA11959A/en unknown
- 2000-06-02 AU AU57254/00A patent/AU778071B2/en not_active Ceased
- 2000-06-02 SV SV2000000096A patent/SV2002000096A/es unknown
- 2000-06-02 KR KR1020017015384A patent/KR20020015333A/ko not_active Withdrawn
- 2000-06-02 CA CA002371158A patent/CA2371158A1/en not_active Abandoned
- 2000-06-02 ES ES00942660T patent/ES2234628T3/es not_active Expired - Lifetime
- 2000-06-02 CZ CZ20014213A patent/CZ20014213A3/cs unknown
- 2000-06-02 EP EP00942660A patent/EP1181283B1/de not_active Expired - Lifetime
- 2000-06-02 HU HU0202897A patent/HUP0202897A3/hu unknown
- 2000-06-02 PL PL00352714A patent/PL352714A1/xx not_active Application Discontinuation
- 2000-06-02 MX MXPA01012483A patent/MXPA01012483A/es not_active Application Discontinuation
- 2000-06-02 IL IL14609400A patent/IL146094A0/xx unknown
- 2000-06-02 EE EEP200100659A patent/EE200100659A/xx unknown
- 2000-06-02 DE DE60017894T patent/DE60017894T2/de not_active Expired - Fee Related
- 2000-06-02 YU YU85601A patent/YU85601A/sh unknown
- 2000-06-02 SK SK1730-2001A patent/SK17302001A3/sk unknown
- 2000-06-02 NZ NZ514881A patent/NZ514881A/en unknown
- 2000-06-02 UY UY26190A patent/UY26190A1/es not_active Application Discontinuation
- 2000-06-02 HR HR20020008A patent/HRP20020008A2/hr not_active Application Discontinuation
2001
- 2001-02-15 US US09/783,584 patent/US6620828B2/en not_active Expired - Fee Related
- 2001-10-09 ZA ZA200108291A patent/ZA200108291B/xx unknown
- 2001-10-17 NO NO20015045A patent/NO20015045L/no not_active Application Discontinuation
- 2001-11-29 IS IS6183A patent/IS6183A/is unknown
2002
- 2002-01-02 MA MA26465A patent/MA25530A1/fr unknown
- 2002-01-03 BG BG106276A patent/BG106276A/bg unknown

Also Published As

Publication number	Publication date
SV2002000096A (es)	2002-06-07
US6620828B2 (en)	2003-09-16
YU85601A (sh)	2004-09-03
NO20015045L (no)	2002-02-04
HUP0202897A3 (en)	2004-12-28
NZ514881A (en)	2003-10-31
SK17302001A3 (sk)	2004-01-08
AU778071B2 (en)	2004-11-11
BG106276A (bg)	2002-10-31
JP2003501420A (ja)	2003-01-14
DE60017894T2 (de)	2005-12-29
AP2001002341A0 (en)	2001-12-31
HRP20020008A2 (en)	2004-02-29
ZA200108291B (en)	2002-12-24
PL352714A1 (en)	2003-09-08
PE20010211A1 (es)	2001-03-16
IL146094A0 (en)	2002-07-25
BR0011585A (pt)	2002-03-19
MA25530A1 (fr)	2002-10-01
KR20020015333A (ko)	2002-02-27
AU5725400A (en)	2000-12-28
EP1181283B1 (de)	2005-02-02
MXPA01012483A (es)	2002-07-30
HUP0202897A2 (hu)	2002-12-28
CA2371158A1 (en)	2000-12-14
IS6183A (is)	2001-11-29
CZ20014213A3 (cs)	2002-04-17
EE200100659A (et)	2003-02-17
US20020025976A1 (en)	2002-02-28
ATE288424T1 (de)	2005-02-15
WO2000075120A1 (en)	2000-12-14
EP1181283A1 (de)	2002-02-27
UA71971C2 (en)	2005-01-17
ES2234628T3 (es)	2005-07-01
EA200101268A1 (ru)	2002-06-27
OA11959A (en)	2006-04-17
CN1359380A (zh)	2002-07-17
NO20015045D0 (no)	2001-10-17
UY26190A1 (es)	2000-12-29

Publication	Publication Date	Title
DE60017894D1 (de)	2005-03-10	Diaminothiazole und ihre verwendung zur inhibierung von proteinkinasen
ATE306487T1 (de)	2005-10-15	Purinhemmer von cyclinabhängiger kinase 2 und ikb-alpha
DE60027479D1 (de)	2006-05-24	Harzstruktur und ihre verwendung
DE69926800D1 (de)	2005-09-22	Benzoheterozyklen und ihre verwendung als mek inhibitoren
DE60016326D1 (de)	2005-01-05	Wasser-absorbierende Zusammensetzung und ihre Verwendung
DE69820397D1 (de)	2004-01-22	Ätzmittel und ihre Verwendung
DE69927971D1 (de)	2005-12-01	Verwendung von peg-ifn-alpha und ribavirin zur behandlung chronischer hepatitis c
DE60231796D1 (de)	2009-05-14	Kit und system zur immobilisierung von objekten im körper
DE69826662D1 (de)	2004-11-04	4-brom or 4-iod-phenylamino-benzhydroxamsäurederivate und ihre anwendung als mek-inhibitoren
DE60010470D1 (de)	2004-06-09	Polyester-polyamidmischungen mit reduzierter gasdurchlässigkeit und geringer trübung
ATE299881T1 (de)	2005-08-15	4-substituierte 7-aza-indolin-2-one und ihre anwendung als protein kinase inhibitoren
DE60015082D1 (de)	2004-11-25	Künstliche peptide mit oberflächenaktivität und ihre verwendung zur herstellung von künstlichen tensiden
DE50012379D1 (de)	2006-05-04	Verwendung von nanoskaligen antischuppenwirkstoffen
DE60027927D1 (de)	2006-06-14	Harzstruktur und ihre verwendung
DE69826693D1 (de)	2004-11-04	Amidinoderivate und ihre verwendung als thrombininhibitoren
ATE267184T1 (de)	2004-06-15	Substituierte 3-phenyl-5-alkoxi-1,3,4-oxdiazol-2- one und ihre verwendung zur hemmung der hormonsensitiven lipase
DE50206094D1 (de)	2006-05-11	Substituierte isoindole und ihre verwendung
DE60017133D1 (de)	2005-02-03	Naphthochinonderivate und ihre verwendung zur behandlung und kontrolle von tuberkulose
DE50008549D1 (de)	2004-12-09	Triazolotriazinone und ihre verwendung
DE60102122D1 (de)	2004-04-01	Zusammensetzung von Poly-1-Butenharz und dessen Verwendung
DE69835006D1 (de)	2006-08-03	Inhibitoren des algenwachstums und ihre verwendung
DE60027429D1 (de)	2006-05-24	Dihydrobenzodiazepinen und deren verwendung zur behandlung von dyslipidämien
DE60322052D1 (de)	2008-08-21	N-acylaminoacetonitril-derivate und ihre verwendung zur kontrolle von parasiten
ATE253059T1 (de)	2003-11-15	Substituierte 3-phenyl-5-alkoxi-1,3,4-oxdiazol-2- one und ihre verwendung als lipase-hemmer
ATE209626T1 (de)	2001-12-15	Alkyloxyamin-substituierte fluorenonderivate und ihre verwendung als proteinkinase-c-inhibitoren

Legal Events

Date	Code	Title	Description
2006-04-13	8364	No opposition during term of opposition
2009-04-23	8339	Ceased/non-payment of the annual fee